Kai‐Feng Xu

3.6k total citations
118 papers, 1.8k citations indexed

About

Kai‐Feng Xu is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Kai‐Feng Xu has authored 118 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Pulmonary and Respiratory Medicine, 50 papers in Physiology and 19 papers in Molecular Biology. Recurrent topics in Kai‐Feng Xu's work include Tuberous Sclerosis Complex Research (40 papers), Neonatal Respiratory Health Research (18 papers) and Renal cell carcinoma treatment (16 papers). Kai‐Feng Xu is often cited by papers focused on Tuberous Sclerosis Complex Research (40 papers), Neonatal Respiratory Health Research (18 papers) and Renal cell carcinoma treatment (16 papers). Kai‐Feng Xu collaborates with scholars based in China, United States and Australia. Kai‐Feng Xu's co-authors include Xinlun Tian, Zhi‐Cheng Jing, Lei Pan, Wenshuai Xu, Yanli Yang, Carl Arneson, Lewis J. Rubin, Kevin Laliberte, Eugene Kotlyar and David G. Kiely and has published in prestigious journals such as Proceedings of the National Academy of Sciences, PLoS ONE and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Kai‐Feng Xu

106 papers receiving 1.8k citations

Peers

Kai‐Feng Xu

PRM

PHYSI

CCM

SURGE

Daniel J. Kass United States

Steven K. Huang United States

Carina Becerril Mexico

C. Magnus Sköld Sweden

Shiro Adachi Japan

José Cisneros Mexico

Julian Ilcheff Borissoff Netherlands

Brigham C. Willis United States

Stephen B. Walsh United Kingdom

Giuseppina Bertorelli Italy

Daniel J. Kass United States

Kai‐Feng Xu

1.7k ×1.8

PRM

375 ×0.9

PHYSI

693 ×2.0

216 ×0.7

CCM

168 ×0.7

SURGE

Citations per year, relative to Kai‐Feng Xu Kai‐Feng Xu (= 1×) peers Daniel J. Kass

Countries citing papers authored by Kai‐Feng Xu

Since Specialization

Citations

This map shows the geographic impact of Kai‐Feng Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kai‐Feng Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kai‐Feng Xu more than expected).

Fields of papers citing papers by Kai‐Feng Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kai‐Feng Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kai‐Feng Xu. The network helps show where Kai‐Feng Xu may publish in the future.

Co-authorship network of co-authors of Kai‐Feng Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Kai‐Feng Xu. A scholar is included among the top collaborators of Kai‐Feng Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kai‐Feng Xu. Kai‐Feng Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Yaqi, Yanli Yang, Shuzhen Meng, et al.. (2025). Progression and mortality of patients with cystic fibrosis in China. Orphanet Journal of Rare Diseases. 20(1). 6–6.

Zheng, Haixia, Yixuan Li, Ting Zhang, et al.. (2025). Interpreting Variants of Uncertain Significance in PCD: Abnormal Splicing Caused by a Missense Variant of DNAAF3. Molecular Genetics & Genomic Medicine. 13(1). e70036–e70036.

Wang, Hanghang, et al.. (2025). Increased malignancy risk in patients with lymphangioleiomyomatosis: findings from a Chinese cohort. Orphanet Journal of Rare Diseases. 20(1). 263–263.

Zhang, Tengyue, Xiaoxin Zhang, Wenshuai Xu, et al.. (2025). Associations of VEGF-D levels with clinical manifestations in lymphangioleiomyomatosis: a cross-sectional analysis of 631 cases. Orphanet Journal of Rare Diseases. 20(1). 255–255.

Zou, Li‐Ping, Kai‐Feng Xu, Wenshuai Xu, et al.. (2024). Long-term safety and influence on growth in patients receiving sirolimus: a pooled analysis. Orphanet Journal of Rare Diseases. 19(1). 299–299. 2 indexed citations

Wang, Hao, Chen Chen, Dandan Hu, et al.. (2024). Sirolimus Safely Used in a Patient After Everolimus-induced Pneumonitis: A Case Report. A2000–A2000.

Si, Xiaoyan, Shafei Wu, Ruie Feng, et al.. (2024). Clinicopathological Characteristics of Inflammatory Myofibroblastic Tumor: A Single Center Retrospective Cohort Study. Thoracic Cancer. 16(1). e15496–e15496. 1 indexed citations

Huang, Jiannan, Ai Ge, Hai‐Wen Lu, et al.. (2023). Updated severity and prognosis score of pulmonary alveolar proteinosis: A multi-center cohort study in China. Frontiers in Medicine. 10. 1058001–1058001. 3 indexed citations

Hu, Dongsheng, Yaping Liu, Ling Yang, et al.. (2023). Sporadic lymphangioleiomyomatosis in a man with somatic mosaicism of TSC2 mutations, a case report. QJM. 117(1). 75–76.

10.

Wang, Yani, Lin‐Yan Wan, Shuhui Yang, et al.. (2023). GOLM1 Promotes Pulmonary Fibrosis through Upregulation of NEAT1. American Journal of Respiratory Cell and Molecular Biology. 70(3). 178–192. 5 indexed citations

11.

Xu, Wenshuai, Peng Liu, Yaping Liu, et al.. (2022). Gene mutations in sporadic lymphangioleiomyomatosis and genotype–phenotype correlation analysis. BMC Pulmonary Medicine. 22(1). 354–354. 2 indexed citations

12.

Jin, Liri, et al.. (2022). Genetic analysis of 18 families with tuberous sclerosis complex. Neurogenetics. 23(3). 223–230.

13.

Chen, Ling, Yan Li, Xiaoyan Xin, et al.. (2021). Long-term follow-up and successful treatment of pulmonary alveolar proteinosis without hypercholesterolemia with statin therapy: a case report. Journal of International Medical Research. 49(4). 3619070974–3619070974. 8 indexed citations

14.

Shen, Lisha, Jinsong Gao, Jun Wang, et al.. (2021). Pregnancy after the diagnosis of lymphangioleiomyomatosis (LAM). Orphanet Journal of Rare Diseases. 16(1). 133–133. 18 indexed citations

15.

Xu, Wenshuai, Xinlun Tian, Yanli Yang, et al.. (2021). The etiology of diffuse cystic lung diseases: an analysis of 1010 consecutive cases in a LAM clinic. Orphanet Journal of Rare Diseases. 16(1). 273–273. 9 indexed citations

16.

Zhao, Caiqi, et al.. (2020). Deficiency of HIF-1α enhances influenza A virus replication by promoting autophagy in alveolar type II epithelial cells. Emerging Microbes & Infections. 9(1). 691–706. 68 indexed citations

17.

Xu, Wenshuai, Lu Zhang, Yu Li, et al.. (2020). Effects of yoga on exercise capacity in patients with lymphangioleiomyomatosis: a nonrandomized controlled study. Orphanet Journal of Rare Diseases. 15(1). 72–72. 8 indexed citations

18.

Gao, Nannan, Wenshuai Xu, Jiadong Ji, et al.. (2020). Lung function and systemic inflammation associated with short-term air pollution exposure in chronic obstructive pulmonary disease patients in Beijing, China. Environmental Health. 19(1). 12–12. 92 indexed citations

19.

Hu, Siqi, Xiuxiu Wu, Wenshuai Xu, et al.. (2019). Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis. Orphanet Journal of Rare Diseases. 14(1). 206–206. 24 indexed citations

20.

Shen, Lisha, Wenshuai Xu, Xiuxiu Wu, et al.. (2018). Functional improvements in patients with lymphangioleiomyomatosis after sirolimus: an observational study. Orphanet Journal of Rare Diseases. 13(1). 34–34. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact